Global Blood Therapeutics Inc. had a significant update for investors at the American Society of Hematology annual meeting Dec. 3, announcing that the US FDA has agreed to a novel accelerated approval pathway for voxelotor for the treatment of sickle cell disease (SCD).
The update could position voxelotor for a potential launch in 2020 as investors have been hoping. The company's stock jumped...







